
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39251712
70937
10.1038/s41598-024-70937-y
Article
Analysis of action of 1,4-naphthoquinone scaffold-derived compounds against acute myeloid leukemia based on network pharmacology, molecular docking and molecular dynamics simulation
Chen Rong 1
Liu Hengfang 2
Meng Weikang 2
Sun Jingyu bengbenghenhao@163.com

2
1 grid.459700.f Department of Oncology, Lishui People’s Hospital, Lishui, 323000 China
2 https://ror.org/027gw7s27 grid.452962.e Department of Hematology Oncology, Taizhou Municipal Hospital, Taizhou, 318000 China
9 9 2024
9 9 2024
2024
14 2104329 1 2024
22 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
1,4-Naphthoquinone scaffold-derived compounds has shown considerable pharmacological properties against cancer, including acute myeloid leukemia (AML) However, its impact and mechanisms in AML are uncertain. In this study, the mechanisms of 1,4-naphthoquinone scaffold-derived compounds against AML were investigated via network pharmacology, molecular docking and molecular dynamics simulation. ASINEX database was used to collect the 1,4-naphthoquinone scaffold-derived compounds, and compounds were extracted from the software to evaluate their drug similarity and toxicity. The potential targets of compounds were retrieved from the SwissTargetPrediction Database and the Similarity Ensemble Approach Database, while the potential targets of AML were obtained from the GeneCards databases and Gene Expression Omnibus. The STRING database was used to construct a protein–protein interaction (PPI) network, topologically and Cyto Hubb plugin of Cytoscape screen the central targets. After selecting the potential key targets, the gene ontology (GO) function annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed for the intersection targets, and a network map of “compounds-potential targets-pathway-disease” were constructed. Molecular docking of the compounds with the core target was performed, and core target with the strongest binding force and 1,4-naphthoquinone scaffold-derived compounds was selected for further molecular dynamics simulation and further molecular mechanics/Poisson–Boltzmann surface area (MM/PBSA) approach verification. In addition, the Bloodspot database was applied to perform the overall survival of core targets. A total of 19 1,4-naphthoquinone scaffold-derived compounds were chosen out, and then 836 targets of compounds, 96 intersection targets of AML were screened. Core targets include STAT3, TLR4, HSP90AA1, JUN, MMP9, PTPRC, JAK2, PTGS2, KIT and CSF1R. GO functional enrichment analysis revealed that 90 biological processes, 10 cell components and 12 molecular functions were enriched while KEGG pathway enrichment analysis revealed 34 enriched signaling pathways. Analysis of KEGG enrichment hinted that these 10 core genes were located in the pathways in cancer, suggesting that 1,4-naphthoquinone scaffold-derived compounds had potential activity against AML. Molecular docking analysis revealed that the binding energies between 1,4-naphthoquinone scaffold-derived compounds and the core proteins were all higher than − 6 kcal/mol, indicating that the 10 core targets all had strong binding ability with compounds. Moreover, a good binding capacity was inferred from molecular dynamics simulations between compound 7 and MMP9. The total binding free energy calculated using the MM/GBSA approach revealed values of − 6356.865 kcal/mol for the MMP9-7 complex. In addition, Bloodspot database results exhibited that HSP90AA1, MMP9 and PTPRC were associated with overall survival. The findings provide foundations for future studies into the interaction underlying the anti-AML potential of compounds with 1,4-naphthoquinone-based scaffold structures. Compounds with 1,4-naphthoquinone-based scaffold structures exhibits considerable potential in mitigating and treating AML through multiple targets and pathways.

Keywords

1,4-Naphthoquinone
Acute myeloid leukemia
Network pharmacology
Molecular docking
Molecular dynamics simulation
Subject terms

Haematological cancer
Drug screening
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancies characterized by clonal proliferation and impaired differentiation of myeloid hematopoietic cells1,2. The incidence rate of AML was 4.3 persons/100,000 persons/year, and the mortality rate was 2.8 persons/100,000 persons/year, seriously endangering human health. The 5-year survival rate of patients was only 24%, and the median overall survival time was only 8.5 months1. Since the 1980s, the “3 + 7” standard treatment regimen for AML (3-day anthracyclines + 7-day cytarabine) has remained almost unchanged. In recent years, the emergence of new targeted drugs and the application of immunotherapy have brought new hope for the treatment of AML3. However, compared with young patients, elderly AML patients are characterized by advanced age, more comorbidities, poor drug tolerance, and a higher incidence of mutated genes with poor prognosis. Low-intensity chemotherapy and demethylation therapy are the main treatment methods, and the 5-year survival rate is less than 10%4. Meanwhile, because AML is highly heterogeneous at cytogenetic and molecular levels, different AML patients often carry different gene mutations, and existing targeted drugs can only benefit patients with corresponding gene mutations3. Therefore, the search for new drugs is still a research hotspot.

Natural products are an important source of rich drug diversity, and the mining of active ingredients in natural products has made great contributions to human treatment of various diseases over the past century, and it would continue to provide an indispensable source of bioactive lead compounds for drug research5,6. Natural products and their derivatives are important components of natural medicines and important sources of drugs included in pharmacopoeia. According to rough estimates, half of the medicines sold in the modern market are derived from natural medicines5. 1,4-naphthoquinone derivatives are common compounds in nature7. Besides good anti-tumor activity, they also have many pharmacological activities such as antibacterial, anti-inflammatory, antioxidant and cardiac protection8. A variety of 1, 4-naphthoquinone derivatives, such as plumbagin, shikonin, and juglone, have been shown to have significant efficacy in cancer treatment9–11. Moreover, the mechanism of action of naphthoquinone against AML was reviewed, and 1, 4-naphthoquinone showed the anti-AML activity through various apoptotic pathway and cellular signaling pathways12, and thus 1, 4-naphthoquinone scaffold-derived compounds could represent the promising compounds against AML.

However, the molecular interactions between 1,4-naphthoquinone scaffold-based compounds and AML-associated proteins are not fully understood. Network pharmacology is an emerging approach to drug analysis that is based on systems biology, multidirectional pharmacology, and network analysis, enabling the construction of “active component-target-gene-disease” networks to reveal drug-disease interactions from a holistic perspective13,14. Moreover, the method is also widely used to gain insight into the therapeutic mechanisms of cancer-related drugs15,16. Therefore, in the present study, the possible mechanism of 1, 4-naphthoquinone scaffold-based compounds in the treatment of AML was analyzed by means of network pharmacology from the aspects of active targets, signal pathways, molecular docking and molecular dynamics simulation, so as to provided theoretical basis for subsequent experimental and clinical studies. A diagram of the workflow is shown in Fig. 1.Fig. 1 The workflow diagram.

Materials and methods

Collection and screening of 1,4-naphthoquinone scaffold-derived compounds

1,4-Naphthoquinone scaffold-derived compounds were sourced from the ASINEX database (http://www.asinex.com). DataWarrior Chemical Data Analysis (https://openmolecules.org/datawarrior/) and Visualization software V6.0.0 were used to evaluate compounds17. 1,4-Naphthoquinone compounds are plotted in the “Structure” function of the software, looking for compounds with similar 1,4-naphthoquinone base structures. Compounds based on the structural framework of 1,4-naphthoquinone scaffolds were then extracted from the software to evaluate their drug similarity and toxicity.

The prediction of drug‑likeness and toxic parameters

The properties of drug-likeness on the 1,4-naphthoquinone scaffold-derived compounds were performed by SwissADME (http://www.swissadme.ch/index.php)18. The filtering standard was based on Lipinski’s rule: Molecular weight (< 500 g/mol) or Topological Polar Surface Area (TPSA) (< 140 Å2) or Moriguchi octanol–water partition coefficient (MLogP) (≤ 4.15) or Hydrogen Bonding Acceptor (HBA) (< 10) or Hydrogen Bonding Donor (HBD) (≤ 5)19. To accept the rule, the molecules should not be violated more than 2 parameters out of 5 parameters. The toxicity of the 1,4-naphthoquinone scaffold-derived compounds were confirmed by Molecular Properties Prediction (https://www.organic-chemistry.org/prog/peo/), and the mutagenicity, tumorigenicity, irritancy, and reproductive effects of compounds are all “none”, which is the inclusion criterion for non-toxicity of the compound20. Compounds with no violations were chosen for further assessment.

Common targets prediction of 1,4-naphthoquinone scaffold-derived compounds and AML

The potential targets of 1,4-naphthoquinone scaffold-derived compounds were predicted using the SwissTargetPrediction Database (STP) (http://www.swisstargetprediction.ch/) and the Similarity Ensemble Approach Database (SEA) (https://sea.bkslab.org/)21,22. The potential targets of AML were identified using the GeneCards databases (https://www.genecards.org) searching for the keyword “acute myeloid leukemia”23 and Gene Expression Omnibus (GEO) database in GSE37307 (https://www.ncbi.nlm.nih.gov/geo/)24. Then the common targets prediction of 1,4-naphthoquinone scaffold-derived compounds and AML were collected using the Venny Website (https://bioinfogp.cnb.csic.es/tools/venny/index.html), and is represented by a Veen diagram.

Establishment of protein–protein interaction (PPI) network and screening of key targets

The potential targets for 1,4-naphthoquinone scaffold-derived compounds and AML were introduced into STRING platform (https://cn.string-db.org/), and then multi-protein analysis function was then applied and “Homo sapiens” was selected25. Remove hidden 9 disconnected nodes from the network and then downloaded PPI data. Then, the data of PPI was imported into Cytoscape 3.7.1 to draw the PPI network and further obtain the top 10 core targets based on the median value of degree, betweenness centrality, and closeness centrality. PPI network was filtered by molecular complex detection algorithm (MCODE) plugin in Cytoscape.

Establishment of GO enrichment analysis and KEGG pathway analysis

The obtained top 10 key targets were imported into David platform (https://david.ncifcrf.gov/)26. Set the Identifier to “OFFICE_GENE_SYMBOL”, species to “Homo sapiens”, and List Type to “Gene List”, respectively. Then, select “GOTERM _BP_DIRECT”, “GOTERM_CC_DIRECT”, “GOTERM_MF_DIRECT” in Gene_Ontology and “KEGG_PATHWAY” in Pathways. GO enrichment analysis and KEGG pathway analysis were performed, and the results were visualized.

Molecular docking

The AutoDock software was used to perform molecular docking between top 2 key targets (STAT3 and TLR4) and 1,4-naphthoquinone scaffold-derived compounds. The 3D structure of 1,4-naphthoquinone scaffold-derived compounds from ChemBio3D software. The crystal structures of target proteins were obtained from the RCSB database (https://www.rcsb.org/)27. Make AutoDockTools 1.5.6 convert ligand and receptor files to pdbqt format and improve their structure by replacing water molecules with hydrogen atoms. AutoDock Vina 1.1.2 was used for molecular docking to obtain the binding energy value, and the combination with the lowest binding energy was visually analyzed by PyMOL 2.4.0 software.

Molecular dynamics simulation

The complex was simulated with 50 ns MD using Gromacs 2023. The protein uses CHARMM 36 field parameters28, and the ligand topology is constructed by GAFF2 field parameters. The protein–ligand complex is placed in a cube box using periodic boundary conditions. The TIP3P water model was used to fill the box with water molecules29. The particle grid Ewald (PME) and Verlet algorithms are used to deal with electrostatic interactions respectively. The heavy atoms of the protein are confined and the steepest descent method is applied to minimize the energy of 50,000 steps. The simulation system was balanced by 100 ps using a gauge ensemble (NVT) and an isothermal isobaric ensemble (NPT). Both van der Waals and Coulomb interactions are calculated using 1.0 nm cutoff values. Finally, the system performed 100 ns molecular dynamics simulations at constant temperature (300 K) and constant pressure (1 bar) with a time step of 2 fs, saving trajectory data every 10 ps. Binding free energy was calculated using the MM/PBSA.py module.

Survival analysis in relation to core targets

Analysis of the overall survival in relation to 10 core targets was performed using the Booldspot (https://www.bloodspot.eu/) database30. A P value < 0.05 was used as a unified screening criterion.

Results

Screening of 1,4-naphthoquinone scaffold-derived compounds for drug-likeness and toxicity properties

First, we retrieved a comprehensive set of 575,302 compounds from the ASINEX database, and then screened them with DataWarrior chemical data analysis and visualization software V5.5.0 to obtain 26 compounds with 1,4-naphthoquinone scaffold (Table S1), and all of which were accepted by Lipinski’s rules. As a promising chemotherapeutic drug, low toxicity is essential, and thus we further predicted the toxic properties of these compounds. The OSIRIS Property Explore was reported to be able to predict the toxicity properties of the compounds, so in present study, 19 compounds were predicted to have no toxicity properties and screened out for further study through OSIRIS Property Explore (Table 1 and Fig. 2).Table 1 The physicochemical properties of the 1,4-naphthoquinone scaffold-derived compounds.

Compound	Lipinski’s rules	Lipinski’s violations
≤ 1	Bioavailability score
> 0.1	TPSA (Å2)
< 140	Toxicity	
MW < 500	HBA < 10	HBD ≤ 5	MLog P ≤ 4.15	Mutagenic	Tumorigenic	Reproductive effective	Irritant	
4	275.73	2	0	1.65	0	0.55	37.38	None	None	None	None	
5	270.37	2	0	3.01	0	0.55	34.14	None	None	None	None	
6	251.24	3	0	0.31	0	0.85	61.08	None	None	None	None	
7	364.3	6	1	1.69	0	0.56	93.18	None	None	None	None	
8	460.32	3	0	3.13	0	0.55	54.45	None	None	None	None	
9	421.67	10	1	2.59	0	0.55	46.17	None	None	None	None	
11	334.37	3	1	0.94	0	0.55	58.64	None	None	None	None	
12	348.4	3	1	1.16	0	0.55	58.64	None	None	None	None	
13	332.40	2	1	1.99	0	0.55	49.41	None	None	None	None	
15	287.70	3	1	0.6	0	0.55	59.31	None	None	None	None	
16	362.42	3	1	1.65	0	0.55	58.64	None	None	None	None	
17	354.81	5	0	− 0.19	0	0.55	83.14	None	None	None	None	
18	389.45	4	1	0.85	0	0.55	69.72	None	None	None	None	
19	375.42	3	1	0.9	0	0.55	69.72	None	None	None	None	
21	368.84	5	0	0.05	0	0.55	83.14	None	None	None	None	
22	353.8	3	0	1.35	0	0.55	53.51	None	None	None	None	
24	400.81	3	1	2.66	0	0.55	67.65	None	None	None	None	
25	413.42	5	0	2	0	0.55	81.92	None	None	None	None	
26	410.38	5	2	1.79	0	0.55	104.95	None	None	None	None	
None means compounds without mutagenic, tumorigenic, reproductive effective and irritant.

Fig. 2 The structure of the screened 1,4-naphthoquinone scaffold-derived compounds.

Acquisition of common targets of 1,4-naphthoquinone scaffold-derived compounds and AML

Then, the targets related to the 19 1,4-naphthoquinone scaffold-derived compounds were retrieved from the SwissTargetPrediction database (STP) (535) and Similarity Ensemble Approach Database (460), respectively (Table S2). After sorting out and removing duplicate targets, 836 targets were collected. A total of 15,746 AML-related targets were obtained from GeneCards database, and while 1505 AML-related targets were collected from GSE37307. 96 potential overlapping targets of compounds and AML were obtained by the website of Venny 2.1.0, which was considered to be differentially expressed genes and designated as potential hub genes for the effects of 1,4-naphthoquinone scaffold-derived compounds on AML (Fig. 3).Fig. 3 Venn diagram showing the targets of the 1,4-naphthoquinone scaffold-derived compounds and AML.

Protein–protein interaction network analysis

To explore the potential mechanism of 1,4-naphthoquinone scaffold-derived compounds for AML, PPI network was constructed based on the degree centrality (DC), betweenness centrality (BC) and closeness centrality (CC) of targets. It can be seen from Fig. 4A that 21 nodes and 155 edges were obtain with DC ≥ 21 as the criterion. Then 10 nodes and 42 edges were acquired under the condition of DC ≥ 25, BC > 0.015 and CC > 0.540. Finally, 10 top targets with greatest performance were obtained, including STAT3, TLR4, HSP90AA1, JUN, MMP9, PTPRC, JAK2, PTGS2, KIT and CSF1R. Moreover, Table 2 was included gene names, DC, BC and CC of these top 10 targets, and these top 10 targets may play the most important role in the progress of 1,4-naphthoquinone scaffold-derived compounds treatment of AML.Fig. 4 The potential targets identified by PPI analysis. (A) The screening process of PPI network topology. 10 targets were obtained from 87 common targets screened by DC, BC and CC. (B) The PPI network. The node color is proportional to the degree value in the network. (C) The network of core 10 targets. (D) Cluster analysis of PPI network.

Table 2 Gene names, degree value, betweenness centrality and closeness centrality of key targets.

Gene name	DC	BC	CC	
STAT3	49	0.185453	0.68254	
TLR4	42	0.093424	0.593103	
HSP90AA1	36	0.145927	0.605634	
JUN	35	0.07966	0.597222	
PTPRC	33	0.038897	0.569536	
MMP9	33	0.044971	0.585034	
JAK2	31	0.021494	0.569536	
PTGS2	30	0.060894	0.547771	
KIT	26	0.025046	0.551282	
CSF1R	25	0.015354	0.5408805	

Then, the obtained 87 potential common targets of 1,4-naphthoquinone scaffold-derived compounds and AML were visualized in Cytoscape3.7.1 software. As shown in Fig. 4B, the collective targets were used to construct the PPI network composed of 87 nodes with 542 edges. Moreover, the color of node from deep to shallow demonstrated that the node DC was from large to small. The PPI among top 10 targets was illustrated in Fig. 4C, two targets with greater degree were STAT3 and TLR4. Moreover, cluster analysis was carried out through the MCODE plugin of Cytoscape to produce highly connected sub-networks and assign targets to 4 group, including cluster 1 (12 nodes and 50 edges), cluster 2 (14 nodes and 57 edges), cluster 3(8 nodes and 12 edges) and cluster 4 (3 nodes and 3edges) (Fig. 4D).

GO enrichment analysis, KEGG pathway analysis and construction of compound-target-pathway-disease network

To identify the top 10 targets functions, GO enrichment analysis and KEGG pathway analysis were performed through David data. Three categories of GO functional annotated targets were attained, including biological process (BP), molecular function (MF) and cellular component (CC). Specifically, the GO functional enrichment analysis included 90 BP, 10 CC and 12 MF. The top 10 items enriched in BP (Fig. 5A) and MF (Fig. 5B) and CC (Fig. 5C) are presented as bubble plots and histograms (Fig. 5D). In addition, BP was mainly associated with positive regulation of nitric oxide biosynthetic process, positive regulation of cell migration, positive regulation of tumor necrosis factor production, inflammatory response and negative regulation of cell proliferation. CC was associated with plasma membrane, cell surface, receptor complex, external side of plasma membrane and integral component of plasma membrane. MF was associated with protein homodimerization activity, identical protein binding, receptor binding, protein phosphatase binding and protein tyrosine kinase activity.Fig. 5 The results of GO enrichment analysis of core targets. (A) Bubble diagram of biological processes (BP). (B) Bubble diagram of cellular components (CC). (C) Bubble diagram of molecular functions (MF). (D) Histogram of GO enrichment analysis.

Furthermore, KEGG pathway analysis-related top 10 targets with 34 signaling pathways were determined, and 10 signaling pathways were selected for mapping and presented them in the form of bubble maps. As shown in Fig. 6A,B, the 10 signaling pathways including pathways in cancer, IL-17 signaling pathway, PI3K-Akt signaling pathway, necroptosis, proteoglycans in cancer, acute myeloid leukemia, TNF signaling pathway, estrogen signaling pathway, NOD-like receptor signaling pathway and MAPK signaling pathway. These data indicate that the protective effects of 1,4-naphthoquinone scaffold-derived compounds against AML are closely linked to these 10 signaling pathways.Fig. 6 The results of KEGG enrichment analysis and pathway network of core targets. (A) Bubble diagram of the top 10 pathways based on KEGG enrichment analysis. (B) Pathway classification of the top 10 pathways.

Moreover, the annotation of KEGG pathways and the involved potential targets are shown in Table 3. The KEGG pathways of pathways in pathways in cancer was visualized using pathview in Fig. 7A. In addition, the network diagram of the relationship between compounds, key targets, top 10 signaling pathways and AML was also established (Fig. 7B).Table 3 Annotation of KEGG pathways with TOP10 enrichment degree and the involved potential targets.

Term	P value	Count	Targets	
Pathways in cancer	1.03E−07	8	CSF1R, HSP90AA1, JUN, STAT3, KIT, JAK2, PTGS2, MMP9	
IL-17 signaling pathway	1.06E−06	6	HSP90AA1, JUN, STAT3, JAK2, TLR4, MMP9	
PI3K-Akt signaling pathway	1.39E−05	5	JUN, STAT3, JAK2, TLR4, MMP9	
Necroptosis	5.49E−05	4	JUN, JAK2, PTGS2, TLR4	
Proteoglycans in cancer	0.022801	3	JUN, STAT3, TLR4	
Acute myeloid leukemia	9.98E−05	4	HSP90AA1, JUN, PTGS2, MMP9	
TNF signaling pathway	1.51E−04	4	HSP90AA1, JUN, STAT3, JAK2	
Estrogen signaling pathway	3.12E−04	5	CSF1R, HSP90AA1, KIT, JAK2, TLR4	
NOD-like receptor signaling pathway	4.73E−04	4	HSP90AA1, STAT3, JAK2, TLR4	
MAPK signaling pathway	8.46E−04	4	JUN, STAT3, JAK2, PTGS2	

Fig. 7 The distribution of key targets in pathways in cancer (A) and the “compounds-targets-pathway-disease network” network involved in the mechanism of 1,4-naphthoquinone scaffold-derived compounds for AML treatment (B).

Molecular docking

To validate the potential therapeutic effects of network pharmacology, molecular docking was employed to evaluate the binding affinity between small molecule drugs and potential targets. The negative binding energy is used to indicate the affinity between the ligand molecule and the target protein of the receptor. Moreover, the lower and more negative binding energy showed that the active compound could bind better to the target protein. Generally, the binding energy between small molecules and proteins is ≤ − 5.0 kcal/mol, indicating that the two have good binding activity31. The parameters of the docking box are collected (Table 4). Meanwhile, the results of binding energies were illustrated as Fig. 8 and Table 5, and it was found that the binding energies of all compounds and the 10 core genes were all less than − 6 kcal/mol. Furthermore, among the core targets, MMP9 and PTGS2 were have the strongest binding affinity with compound 7 and compound 25, which are − 12.4, − 11.6, − 12.4 and − 11.1 kcal/mol respectively. Furthermore, the magnified image of molecular docking of compound 7 and compound 25 with MMP9 and PTGS2 are shown in Fig. 9.Table 4 Grid docking parameters in molecular docking.

Target name	PDB ID	X center	Y center	Z center	
STAT3	4zia	106.71	40.089	132.531	
TLR4	4g8a	− 24.653	3.617	− 33.381	
HSP90AA1	6gr5	14.94	3.036	17.654	
JUN	4y46	8.749	− 20.145	− 28.212	
PTPRC	4zrt	5.48	− 0.748	5.312	
MMP9	4h3x	11.436	11.436	3.893	
JAK2	8c09	21.25	− 7.137	− 11.562	
PTGS2	5ikt	159.813	197.004	207.414	
KIT	4u0i	38.456	16.566	50.71	
CSF1R	8cgc	55.92	41.374	0.405	

Fig. 8 Molecular docking heat map of 1,4-naphthoquinone scaffold-derived compounds and core targets.

Table 5 Molecular docking results between the 1,4-naphthoquinone scaffold-derived compounds and hub targets.

Compounds	Binding energy (kJ/mol)	
STAT3	TLR4	HSP90AA1	JUN	PTPRC	MMP9	JAK2	PTGS2	KIT	CSF1R	
4	− 7.5	− 8.0	− 7.6	− 8.1	− 6.5	− 8.2	− 7.6	− 7.8	− 7.4	− 8.4	
5	− 7.1	− 8.3	− 7.4	− 8.1	− 6.4	− 8.2	− 7.4	− 8.0	− 7.3	− 8.9	
6	− 7.2	− 8.0	− 7.8	− 7.7	− 6.5	− 9.4	− 7.5	− 9.1	− 7.7	− 8.1	
7	− 8.6	− 10.4	− 10.1	− 9.9	− 8.5	− 12.4	− 9.4	− 12.1	− 9.9	− 10.0	
8	− 7.9	− 9.2	− 9.7	− 8.9	− 8.2	− 10.9	− 8.3	− 9.0	− 9.6	− 9.3	
9	− 7.9	− 9.5	− 8.7	− 8.4	− 7.1	− 9.7	− 8.2	− 10.1	− 8.4	− 9.5	
11	− 7.5	− 8.4	− 8.6	− 8.2	− 7.1	− 9.5	− 8.6	− 8.5	− 8.6	− 8.7	
12	− 7.6	− 8.4	− 8.7	− 8.4	− 6.6	− 9.0	− 8.6	− 8.8	− 8.6	− 9.0	
13	− 7.6	− 8.8	− 9.0	− 8.4	− 7.2	− 9.7	− 8.4	− 9.0	− 8.6	− 8.8	
15	− 7.3	− 7.7	− 8.0	− 7.7	− 6.8	− 9.2	− 7.7	− 7.6	− 7.2	− 8.3	
16	− 7.5	− 8.6	− 9.1	− 8.7	− 7.0	− 10.0	− 8.7	− 8.7	− 8.7	− 9.3	
17	− 7.1	− 7.4	− 8.3	− 8.7	− 6.6	− 9.7	− 8.2	− 8.4	− 8.0	− 9.4	
18	− 8.0	− 9.5	− 9.5	− 8.8	− 7.8	− 9.9	− 8.4	− 9.1	− 8.7	− 8.8	
19	− 8.0	− 8.9	− 8.5	− 9.0	− 7.3	− 9.6	− 8.1	− 9.2	− 8.2	− 9.2	
21	− 7.0	− 8.2	− 8.4	− 8.5	− 6.6	− 9.1	− 7.9	− 7.9	− 8.0	− 8.5	
22	− 7.8	− 9.0	− 8.9	− 9.0	− 6.9	− 9.3	− 8.4	− 9.4	− 8.4	− 9.6	
24	− 8.7	− 10.6	− 10.0	− 9.6	− 7.8	− 10.2	− 9.2	− 10.7	− 9.5	− 9.9	
25	− 8.5	− 9.7	− 10.3	− 10.9	− 8.3	− 11.6	− 9.6	− 11.1	− 9.7	− 10.5	
26	− 8.6	− 9.7	− 10.5	− 10.0	− 9.1	− 10.9	− 9.3	− 10.8	− 9.6	− 10.4	

Fig. 9 Magnified image of molecular docking results between the compound 7 and compound 25 with MMP9 and PTGS2, respectively.

Molecular dynamics simulation

As per molecular docking findings, MMP9 with the strongest binding force and compound 7 was selected for further molecular dynamics simulation verification. Root mean square deviation (RMSD) is a good indicator of the conformational stability of proteins and ligands, and also a measure of the degree of deviation from the starting position of the atom. The smaller the RMSD, the better the conformational stability. Therefore, RMSD is used to evaluate the balance of the simulation system. As shown in Fig. 10A, the movement of the protein/small molecule complex gradually converges during about 61 ns simulation and maintains relatively stable fluctuations in the middle and late stages of the simulation. Moreover, RMSD was maintained at around 10 Å in the middle and late stages of the simulation, meaning that the binding of small molecules did not lead to sustained and significant changes in protein conformation. Root mean square fluctuation (RMSF) can indicate the flexibility of amino acid residues in a protein. As shown in Fig. 10B,C, the receptor protein is composed of two chains, the protein is relatively flexible as a whole. Radius of Gyration (Rg) can be used to describe the change of the overall structure, and it can be used to characterize the tightness of the protein structure. The greater the change of Rg, the more expanded the system. As can be seen from Fig. 10D, the fluctuation of the binding system is relatively stable after 61 ns, and the Rg value fluctuates around 23A, indicating that the binding of small molecules makes the system denser and more tightly bound.Fig. 10 Molecular dynamics simulation between compound 7 and MMP9 protein. (A,B) RMSF; (C) RMSD; (D) Rg; (E) MM-PBSA.

The binding conformation of complex was used to calculate the binding free energy using the MM/PBSA method. The binding energy of complex was − 26,555.284 kJ/mol. Negative values indicate that the molecule has binding affinity for the target protein, and lower value indicates stronger binding. Additionally, the van der Waals contribution (− 135.952 kJ/mol) and electrostatic contribution (− 26,421.700 kJ/mol) of the small molecule was favorable to the binding of target protein (Fig. 10E). All in all, MMP9 and compound 7 had a good binding effect.

Clinical relevance of core genes

The 10 core targets were selected based on the results in the PPI network and then imported into the Bloodspot database for clinical relevance analysis. The results from the Bloodspot database showed that the expression level of HSP90AA1, MMP9 and PTPRC was significantly correlated with overall survival (P < 0.05), while the expression of the other core targets was not significantly related to the overall survival of AML patients (Fig. 11). This result suggested that 1,4-naphthoquinone scaffold-derived compounds may affect the prognosis of AML patients by regulating targets such as MMP9 and HSP90AA1.Fig. 11 Overall survival analysis of core gene in the Bloodspot database.

Discussion

AML is a heterogeneous hematological malignancy that occurs in the elderly and has complex cytogenetic and molecular biological features1. Chemotherapy is often the preferred treatment for patients with AML. However, the use of chemotherapy drugs is linked with significant side effects, unpredictable clinical outcomes, ultimately leading to treatment failure3.

Accumulating evidence indicates that natural products have a variety of special structures and novel biological activities, and are an important source of anti-tumor drugs5,6. 1,4-naphthoquinone is a small aromatic ring compound with many biological activities, which has been widely used in the treatment of many diseases, including AML12. Structurally, 1,4-naphthoquinone is a bicarbonyl ring with abundant active modification sites, and it is easy to form hydrogen bonds, hydrophobicity and other forces29. Among them, natural products of 1, 4-naphthoquinone derivatives have been shown to have significant efficacy in cancer treatment10–12. The development of 1, 4-naphthoquinone derivatives is one of the important directions of anti-tumor drug research and development. However, the complexes underlying the anti-cancer effects of compounds produced from 1,4-naphthoquinone scaffold with AML remain unclear.

Network pharmacology that uses systems biology theory can determine the course of compounds in disease treatment from the whole level, systematically predict and reveal the mechanism of action of drugs13–16. Therefore, this may be promising research method in the field of the action of 1,4-naphthoquinone scaffold-derived compounds against AML. Thus, to further clarify the possible targets and pathways underlying the anti-AML effect of 1,4-naphthoquinone scaffold-derived compounds, we used network pharmacology to construct biological action networks, then GO function and KEGG enrichment analyses of core targets were performed, further verified them through molecular docking and molecular dynamics simulation, and tried to explore and analyze the potential targets and mechanism of action of 1,4-naphthoquinone scaffold-derived compounds against AML.

In our study, preliminary results showed that 10 core targets, including STAT3, TLR4, HSP90AA1, JUN, MMP9, PTPRC, JAK2, PTGS2, KIT and CSF1R, that might be the key targets of 1,4-naphthoquinone scaffold-derived compounds against AML were identified. STAT3 is a recognized oncogenic transcription factor, and abnormal activation of STAT3 signaling pathway is associated with a variety of tumors, including AML32,33. Moreover, STAT3 gene is highly expressed in AML patients, and is related to the immune typing and risk of patients34. TLR4 is a pattern recognition receptor that can bind both exogenous and endogenous ligands. It is expressed by acute myeloid leukemia (AML) cells, several bone marrow stromal cells, and non-leukemia cells involved in inflammation35. Moreover, studies showed that TLR4 expression by AML cells is associated with an adverse prognosis, and TLR4 inhibition can have a chemosensitizing and/or direct antileukemic effect36. HSP90AA1, also known as LAP2/HSPC1, encodes a protein-chaperone protein that plays a major role in protein folding and stabilization as a homodimer, and largely determines tumor proliferation, survival, invasion, metastasis, and angiogenesis by regulating multiple cancer-associated proteins37. The study found that AML patients with higher levels of HSP90AA1 had lower remission rates and were associated with poorer prognosis for AML38,39. Moreover, in vivo study found that indirubin could exhibit leukemia cells proliferation via Targeting HSP90AA140. JUN, also called activator protein-1 (AP-1), is an important modulator in several immune disorders and carcinomas41. Higher levels of AP-1 components were found in AML patients, and AP-1 may provide hematologists with important information on diagnostic criteria and can highly predict the survival rate of newly diagnosed AML patients42. MMP9 is a member of the matrix metalloproteinase (MMP) protein family, and it is found to play a critical role in AML by increasing the invasive properties of malignant myeloblasts43. A significantly lower expression level of MMP-9 in AML-patients compared to normal controls44. Moreover, study showed that patients with lower MMP-9 levels tended to have longer survival times44. PTPRC, also known as CD45 (encoded by the PTPRC gene), is a recognized cell surface marker in nucleated hematopoietic cells, and it is thought to contribute to the development of disease and the progression of AML45,46. Guo et al. found that overexpression of PTPRC indicated poor prognosis in pediatric AML patients, and its expression level was correlated with the infiltration level of activated dendritic cells, thus PTPRC could be a promising immunotherapy target for pediatric AML47. JAK2 is a nonreceptor tyrosine kinase which transmits information to the nucleus via the signal transducer and activator of transcriptions (STATs), where it plays various biological roles48. The study found that JAK2 was not only the most commonly mutated gene in patients with myeloproliferative neoplasms (MPN), but was also present in patients with initial AML and AML-MPN49. JAK2 mutation can continuously activate JAK2-STAT signaling pathway and participate in the occurrence and development of acute leukemia49. PTGS2, also known as cyclooxygenase-2 (COX-2), is considered as a component of inflammatory reactions and is directly related to the process of inflammation, pain, angiogenesis, and cancer50. In the AML cell lines, tumor angiogenesis is activated through the induction of COX-2 expression51, moreover methylation of PTGS2 may play a role in the initiation and leukemogenesis phases of AML. Furthermore, PTGS2 can be considered as diagnostic biomarkers for AML52. KIT (CD117) is a transmembrane protein and is detected in a variety of human neoplastic diseases, including AML53. Moreover, KIT is a specific marker for the myeloid lineage, which is expressed early during hematopoietic differentiation and can aid the diagnosis of AML in difficult cases54. However, inhibition of wild-type KIT is not always satisfactory in AML53. CSF1R is a cell surface glycoprotein encoded by the CSF1R gene located on the distal end of the long arm chromosome 5 (5q32)55. More importantly, analysis of CSF1R expression levels in AML patient samples found a correlation between high levels of CSF1R expression and shorter overall survival56. Meanwhile, GO enrichment analysis and KEGG analysis identified many enriched pathways are involved in the effects of 1,4-naphthoquinone scaffold-derived compounds against AML. More importantly, the molecular docking results showed that 1,4-naphthoquinone scaffold-derived compounds could spontaneously interact with these core targets. Among these compounds, compound 7 had a good binding effect with MMP9 through molecular dynamics simulation and MM/GBSA approach. In addition, the results of survival analysis showed that the expression level of HSP90AA1, MMP9 and PTPRC was significantly correlated with overall survival. However, the present study has certain limitations. 1, 4-naphthoquinone scaffold-derived compounds were not commercially available and hard to synthesize by ourselves in our study, and it is challenging to fully elucidate the anti-AML function of the compounds through additional biological experiments, including in vivo and in vitro models. Thus, this is another difficult subject for us to study in the future.

Conclusion

In conclusion, the current study combines network pharmacology, molecular docking and molecular dynamics simulation to firstly elucidate the molecular and pharmacological mechanisms of 1,4-naphthoquinone scaffold-derived compounds against AML. However, the in-depth study of the underlying molecular mechanisms needs to be further explored and verified.

Supplementary Information

Supplementary Table S1.

Supplementary Table S2.

Abbreviations

AML Acute myeloid leukemia

PPI Protein–protein interaction

GEO Gene Expression Omnibus

MCODE Molecular complex detection algorithm

GO Gene ontology

KEGG Kyoto Encyclopedia of Genes and Genomes

DC Degree centrality

BC Betweenness centrality

CC Closeness centrality

MM/PBSA Molecular mechanics/Poisson–Boltzmann surface area

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-70937-y.

Acknowledgements

We thank all authors for their contributions and support.

Author contributions

Conception and design: R C and JY S; Provision of study materials: R C, HF L and JY S; Collection and assembly of data: R C, HF L, WK M; Data analysis and interpretation: R C, HF L, WK M; Manuscript writing: all authors; Final approval of the manuscript: all authors. All authors agree to publish this paper. 

Data availability

All data generated or analysed during this study are included in this published article [and its supplementary information files] and available from the corresponding author on reasonable request.

Competing interests

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Shallis RM Wang R Davidoff A Ma X Zeidan AM Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges Blood Rev. 2019 36 70 87 10.1016/j.blre.2019.04.005 31101526
Shallis, R. M., Wang, R., Davidoff, A., Ma, X. & Zeidan, A. M. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 36, 70–87 (2019).31101526 10.1016/j.blre.2019.04.005
2. Madanat YF Kalaycio ME Nazha A Advances in acute myeloid leukemia genomics, where do we stand in 2018? Acta Med. Acad. 2019 48 1 35 44 10.5644/ama2006-124.240 31264431
Madanat, Y. F., Kalaycio, M. E. & Nazha, A. Advances in acute myeloid leukemia genomics, where do we stand in 2018?. Acta Med. Acad. 48(1), 35–44 (2019).31264431 10.5644/ama2006-124.240
3. Greiner J Götz M Wais V Increasing role of targeted immunotherapies in the treatment of AML Int. J. Mol. Sci. 2022 23 6 3304 10.3390/ijms23063304 35328721
Greiner, J., Götz, M. & Wais, V. Increasing role of targeted immunotherapies in the treatment of AML. Int. J. Mol. Sci. 23(6), 3304 (2022).35328721 10.3390/ijms23063304
4. Martínez-Cuadrón D Serrano J Gil C Tormo M Martínez-Sánchez P Pérez-Simón JA Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: Changing everything to change nothing? Leukemia 2021 35 6 1571 1585 10.1038/s41375-020-01058-4 33077867
Martínez-Cuadrón, D. et al. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: Changing everything to change nothing?. Leukemia 35(6), 1571–1585 (2021).33077867 10.1038/s41375-020-01058-4
5. Yang GX Ma GL Li H Huang T Xiong J Hu JF Advanced natural products chemistry research in China between 2015 and 2017 Chin. J. Nat. Med. 2018 16 12 881 906 30595214
Yang, G. X. et al. Advanced natural products chemistry research in China between 2015 and 2017. Chin. J. Nat. Med. 16(12), 881–906 (2018).30595214
6. Mansoori B Mohammadi A Amin Doustvandi M Mohammadnejad F Kamari F Gjerstorff MF Photodynamic therapy for cancer: Role of natural products Photodiagnosis Photodyn. Ther. 2019 26 394 404 10.1016/j.pdpdt.2019.04.033
Mansoori, B. et al. Photodynamic therapy for cancer: Role of natural products. Photodiagnosis Photodyn. Ther. 26, 394–404 (2019).10.1016/j.pdpdt.2019.04.033
7. Klaus V Hartmann T Gambini J Graf P Stahl W Hartwig A 1,4-Naphthoquinones as inducers of oxidative damage and stress signaling in HaCaT human keratinocytes Arch. Biochem. Biophys. 2010 496 2 93 100 10.1016/j.abb.2010.02.002 20153715
Klaus, V. et al. 1,4-Naphthoquinones as inducers of oxidative damage and stress signaling in HaCaT human keratinocytes. Arch. Biochem. Biophys. 496(2), 93–100 (2010).20153715 10.1016/j.abb.2010.02.002
8. Aminin D Polonik S 1,4-Naphthoquinones: Some biological properties and application Chem. Pharm. Bull. (Tokyo) 2020 68 1 46 57 10.1248/cpb.c19-00911 31902901
Aminin, D. & Polonik, S. 1,4-Naphthoquinones: Some biological properties and application. Chem. Pharm. Bull. (Tokyo) 68(1), 46–57 (2020).31902901 10.1248/cpb.c19-00911
9. Liu Y Cai Y He C Chen M Li H Anticancer properties and pharmaceutical applications of plumbagin: A review Am. J. Chin. Med. 2017 45 3 423 441 10.1142/S0192415X17500264 28359198
Liu, Y., Cai, Y., He, C., Chen, M. & Li, H. Anticancer properties and pharmaceutical applications of plumbagin: A review. Am. J. Chin. Med. 45(3), 423–441 (2017).28359198 10.1142/S0192415X17500264
10. Lu JJ Bao JL Wu GS Xu WS Huang MQ Chen XP Quinones derived from plant secondary metabolites as anti-cancer agents Anticancer Agents Med. Chem. 2013 13 3 456 463 22931417
Lu, J. J. et al. Quinones derived from plant secondary metabolites as anti-cancer agents. Anticancer Agents Med. Chem. 13(3), 456–463 (2013).22931417
11. Ahmad T Suzuki YJ Juglone in oxidative stress and cell signaling Antioxidants (Basel) 2019 8 4 91 10.3390/antiox8040091 30959841
Ahmad, T. & Suzuki, Y. J. Juglone in oxidative stress and cell signaling. Antioxidants (Basel) 8(4), 91 (2019).30959841 10.3390/antiox8040091
12. Lee MH Lapidus RG Ferraris D Emadi A Analysis of the mechanisms of action of naphthoquinone-based anti-acute myeloid leukemia chemotherapeutics Molecules 2019 24 17 3121 10.3390/molecules24173121 31466259
Lee, M. H., Lapidus, R. G., Ferraris, D. & Emadi, A. Analysis of the mechanisms of action of naphthoquinone-based anti-acute myeloid leukemia chemotherapeutics. Molecules 24(17), 3121 (2019).31466259 10.3390/molecules24173121
13. Zhao L Zhang H Li N Chen J Xu H Wang Y Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formula J. Ethnopharmacol. 2023 309 116306 10.1016/j.jep.2023.116306 36858276
Zhao, L. et al. Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formula. J. Ethnopharmacol. 309, 116306 (2023).36858276 10.1016/j.jep.2023.116306
14. Yuan Z Pan Y Leng T Chu Y Zhang H Ma J Progress and prospects of research ideas and methods in the network pharmacology of traditional Chinese medicine J. Pharm. Pharm. Sci. 2022 25 218 226 10.18433/jpps32911 35760072
Yuan, Z. et al. Progress and prospects of research ideas and methods in the network pharmacology of traditional Chinese medicine. J. Pharm. Pharm. Sci. 25, 218–226 (2022).35760072 10.18433/jpps32911
15. Sun Z Wang Y Pang X Wang X Zeng H Mechanisms of polydatin against spinal cord ischemia-reperfusion injury based on network pharmacology, molecular docking and molecular dynamics simulation Bioorg. Chem. 2023 140 106840 10.1016/j.bioorg.2023.106840 37683540
Sun, Z., Wang, Y., Pang, X., Wang, X. & Zeng, H. Mechanisms of polydatin against spinal cord ischemia-reperfusion injury based on network pharmacology, molecular docking and molecular dynamics simulation. Bioorg. Chem. 140, 106840 (2023).37683540 10.1016/j.bioorg.2023.106840
16. Sun T Quan W Peng S Yang D Liu J He C Network pharmacology-based strategy combined with molecular docking and in vitro validation study to explore the underlying mechanism of Huo Luo Xiao Ling Dan in treating atherosclerosis Drug Des. Dev. Ther. 2022 16 1621 1645 10.2147/DDDT.S357483
Sun, T. et al. Network pharmacology-based strategy combined with molecular docking and in vitro validation study to explore the underlying mechanism of Huo Luo Xiao Ling Dan in treating atherosclerosis. Drug Des. Dev. Ther. 16, 1621–1645 (2022).10.2147/DDDT.S357483
17. López-López E Naveja JJ Medina-Franco JL DataWarrior: An evaluation of the open-source drug discovery tool Expert Opin. Drug Discov. 2019 14 4 335 341 10.1080/17460441.2019.1581170 30806519
López-López, E., Naveja, J. J. & Medina-Franco, J. L. DataWarrior: An evaluation of the open-source drug discovery tool. Expert Opin. Drug Discov. 14(4), 335–341 (2019).30806519 10.1080/17460441.2019.1581170
18. Daina A Michielin O Zoete V SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules Sci. Rep. 2017 7 42717 10.1038/srep42717 28256516
Daina, A., Michielin, O. & Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717 (2017).28256516 10.1038/srep42717
19. Nendza M Müller M Screening for low aquatic bioaccumulation. 1. Lipinski's 'Rule of 5' and molecular size SAR QSAR Environ. Res. 2010 21 5–6 495 512 10.1080/1062936X.2010.502295 20818584
Nendza, M. & Müller, M. Screening for low aquatic bioaccumulation. 1. Lipinski’s “Rule of 5” and molecular size. SAR QSAR Environ. Res. 21(5–6), 495–512 (2010).20818584 10.1080/1062936X.2010.502295
20. Ismail NZ Mohamed WAS Ab Rahim N Hashim NM Adebayo IA Mohamad Zain NN Molecular docking and molecular dynamic simulations of apoptosis proteins with potential anticancer compounds present in Clinacanthus nutans extract using gas chromatography-mass spectrometry J. Biomol. Struct. Dyn. 2023 41 13 6104 6120 10.1080/07391102.2022.2101530 35899385
Ismail, N. Z. et al. Molecular docking and molecular dynamic simulations of apoptosis proteins with potential anticancer compounds present in Clinacanthus nutans extract using gas chromatography-mass spectrometry. J. Biomol. Struct. Dyn. 41(13), 6104–6120 (2023).35899385 10.1080/07391102.2022.2101530
21. Daina A Michielin O Zoete V SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules Nucleic Acids Res. 2019 47 W1 W357 W364 10.1093/nar/gkz382 31106366
Daina, A., Michielin, O. & Zoete, V. SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 47(W1), W357–W364 (2019).31106366 10.1093/nar/gkz382
22. Gu S Lai LH Associating 197 Chinese herbal medicine with drug targets and diseases using the similarity ensemble approach Acta Pharmacol. Sin. 2020 41 3 432 438 10.1038/s41401-019-0306-9 31530902
Gu, S. & Lai, L. H. Associating 197 Chinese herbal medicine with drug targets and diseases using the similarity ensemble approach. Acta Pharmacol. Sin. 41(3), 432–438 (2020).31530902 10.1038/s41401-019-0306-9
23. Stelzer G Rosen N Plaschkes I Zimmerman S Twik M Fishilevich S The GeneCards Suite: From gene data mining to disease genome sequence analyses Curr. Protoc. Bioinform. 2016 54 1.30.1 1.30.33 10.1002/cpbi.5
Stelzer, G. et al. The GeneCards Suite: From gene data mining to disease genome sequence analyses. Curr. Protoc. Bioinform. 54, 1.30.1-1.30.33 (2016).10.1002/cpbi.5
24. Jia G Jiang X Li Z Ding X Lei L Xu S Decoding the mechanism of Shen Qi Sha Bai decoction in treating acute myeloid leukemia based on network pharmacology and molecular docking Front. Cell Dev. Biol. 2021 9 796757 10.3389/fcell.2021.796757 34988084
Jia, G. et al. Decoding the mechanism of Shen Qi Sha Bai decoction in treating acute myeloid leukemia based on network pharmacology and molecular docking. Front. Cell Dev. Biol. 9, 796757 (2021).34988084 10.3389/fcell.2021.796757
25. Szklarczyk D Kirsch R Koutrouli M Nastou K Mehryary F Hachilif R The STRING database in 2023: Protein–protein association networks and functional enrichment analyses for any sequenced genome of interest Nucleic Acids Res. 2023 51 D1 D638 D646 10.1093/nar/gkac1000 36370105
Szklarczyk, D. et al. The STRING database in 2023: Protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51(D1), D638–D646 (2023).36370105 10.1093/nar/gkac1000
26. Dennis G Jr Sherman BT Hosack DA Yang J Gao W Lane HC DAVID: Database for annotation, visualization, and integrated discovery Genome Biol. 2003 4 5 P3 10.1186/gb-2003-4-5-p3 12734009
Dennis, G. Jr. et al. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. 4(5), P3 (2003).12734009 10.1186/gb-2003-4-5-p3
27. Burley SK Bhikadiya C Bi C RCSB Protein Data bank: Tools for visualizing and understanding biological macromolecules in 3D Protein Sci. 2022 31 12 e4482 10.1002/pro.4482 36281733
Burley, S. K. et al. RCSB Protein Data bank: Tools for visualizing and understanding biological macromolecules in 3D. Protein Sci. 31(12), e4482 (2022).36281733 10.1002/pro.4482
28. Jo S Kim T Iyer VG CHARMM-GUI: A web-based graphical user interface for CHARMM J. Comput. Chem. 2008 29 11 1859 1865 10.1002/jcc.20945 18351591
Jo, S. et al. CHARMM-GUI: A web-based graphical user interface for CHARMM. J. Comput. Chem. 29(11), 1859–1865 (2008).18351591 10.1002/jcc.20945
29. Mark P Nilsson L Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K J. Phys. Chem. A 2001 105 9954 9960 10.1021/jp003020w
Mark, P. & Nilsson, L. Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. J. Phys. Chem. A 105, 9954–9960 (2001).10.1021/jp003020w
30. Bagger FO Sasivarevic D Sohi SH BloodSpot: A database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis Nucleic Acids Res. 2016 44 D1 D917 D924 10.1093/nar/gkv1101 26507857
Bagger, F. O. et al. BloodSpot: A database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. Nucleic Acids Res. 44(D1), D917–D924 (2016).26507857 10.1093/nar/gkv1101
31. Vanommeslaeghe K Hatcher E Acharya C CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields J. Comput. Chem. 2010 31 4 671 690 10.1002/jcc.21367 19575467
Vanommeslaeghe, K. et al. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem. 31(4), 671–690 (2010).19575467 10.1002/jcc.21367
32. Hirose R Miura T Sha R A method for detecting covalent modification of sensor proteins associated with 1,4-naphthoquinone-induced activation of electrophilic signal transduction pathways J. Toxicol. Sci. 2012 37 5 891 898 10.2131/jts.37.891 23037999
Hirose, R. et al. A method for detecting covalent modification of sensor proteins associated with 1,4-naphthoquinone-induced activation of electrophilic signal transduction pathways. J. Toxicol. Sci. 37(5), 891–898 (2012).23037999 10.2131/jts.37.891
33. Furtek SL Backos DS Matheson CJ Strategies and approaches of targeting STAT3 for cancer treatment ACS Chem. Biol. 2016 11 2 308 318 10.1021/acschembio.5b00945 26730496
Furtek, S. L. et al. Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chem. Biol. 11(2), 308–318 (2016).26730496 10.1021/acschembio.5b00945
34. Bruserud Ø Nepstad I Hauge M STAT3 as a possible therapeutic target in human malignancies: Lessons from acute myeloid leukemia Expert Rev. Hematol. 2015 8 1 29 41 10.1586/17474086.2015.971005 25374305
Bruserud, Ø. et al. STAT3 as a possible therapeutic target in human malignancies: Lessons from acute myeloid leukemia. Expert Rev. Hematol. 8(1), 29–41 (2015).25374305 10.1586/17474086.2015.971005
35. Curran E Corrales L Kline J Targeting the innate immune system as immunotherapy for acute myeloid leukemia Front. Oncol. 2015 5 83 10.3389/fonc.2015.00083 25914882
Curran, E., Corrales, L. & Kline, J. Targeting the innate immune system as immunotherapy for acute myeloid leukemia. Front. Oncol. 5, 83 (2015).25914882 10.3389/fonc.2015.00083
36. Bruserud Ø Reikvam H Brenner AK Toll-like receptor 4, osteoblasts and leukemogenesis; The lesson from acute myeloid leukemia Molecules 2022 27 3 735 10.3390/molecules27030735 35163998
Bruserud, Ø., Reikvam, H. & Brenner, A. K. Toll-like receptor 4, osteoblasts and leukemogenesis; The lesson from acute myeloid leukemia. Molecules 27(3), 735 (2022).35163998 10.3390/molecules27030735
37. Taipale M Jarosz DF Lindquist S HSP90 at the hub of protein homeostasis: Emerging mechanistic insights Nat. Rev. Mol. Cell Biol. 2010 11 7 515 528 10.1038/nrm2918 20531426
Taipale, M., Jarosz, D. F. & Lindquist, S. HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 11(7), 515–528 (2010).20531426 10.1038/nrm2918
38. Flandrin P Guyotat D Duval A Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells Cell Stress Chaperones 2008 13 3 357 364 10.1007/s12192-008-0035-3 18386162
Flandrin, P. et al. Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells. Cell Stress Chaperones 13(3), 357–364 (2008).18386162 10.1007/s12192-008-0035-3
39. Zhang Z Zhao L Wei X Integrated bioinformatic analysis of microarray data reveals shared gene signature between MDS and AML Oncol. Lett. 2018 16 4 5147 5159 30214614
Zhang, Z. et al. Integrated bioinformatic analysis of microarray data reveals shared gene signature between MDS and AML. Oncol. Lett. 16(4), 5147–5159 (2018).30214614
40. Yao Y Li X Yang X Indirubin, an active component of Indigo naturalis, exhibits inhibitory effects on leukemia cells via targeting HSP90AA1 and PI3K/Akt pathway Anticancer Agents Med. Chem. 2024 24 9 718 727 10.2174/0118715206258293231017063340 38347773
Yao, Y. et al. Indirubin, an active component of Indigo naturalis, exhibits inhibitory effects on leukemia cells via targeting HSP90AA1 and PI3K/Akt pathway. Anticancer Agents Med. Chem. 24(9), 718–727 (2024).38347773 10.2174/0118715206258293231017063340
41. Ye N Ding Y Wild C Small molecule inhibitors targeting activator protein 1 (AP-1) J. Med. Chem. 2014 57 16 6930 6948 10.1021/jm5004733 24831826
Ye, N. et al. Small molecule inhibitors targeting activator protein 1 (AP-1). J. Med. Chem. 57(16), 6930–6948 (2014).24831826 10.1021/jm5004733
42. Trop-Steinberg S Azar Y AP-1 expression and its clinical relevance in immune disorders and cancer Am. J. Med. Sci. 2017 353 5 474 483 10.1016/j.amjms.2017.01.019 28502334
Trop-Steinberg, S. & Azar, Y. AP-1 expression and its clinical relevance in immune disorders and cancer. Am. J. Med. Sci. 353(5), 474–483 (2017).28502334 10.1016/j.amjms.2017.01.019
43. Klein G Vellenga E Fraaije MW The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia Crit. Rev. Oncol. Hematol. 2004 50 2 87 100 10.1016/j.critrevonc.2003.09.001 15157658
Klein, G. et al. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit. Rev. Oncol. Hematol. 50(2), 87–100 (2004).15157658 10.1016/j.critrevonc.2003.09.001
44. Lin LI Lin DT Chang CJ Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: Potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia Br. J. Haematol. 2002 117 4 835 841 10.1046/j.1365-2141.2002.03510.x 12060118
Lin, L. I. et al. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: Potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br. J. Haematol. 117(4), 835–841 (2002).12060118 10.1046/j.1365-2141.2002.03510.x
45. Qian D Liu L Zhu T JAK2 and PTPRC mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus Clin. Rheumatol. 2020 39 2 443 448 10.1007/s10067-019-04778-w 31760539
Qian, D. et al. JAK2 and PTPRC mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin. Rheumatol. 39(2), 443–448 (2020).31760539 10.1007/s10067-019-04778-w
46. Guo L Chen L Wang H CD45 correlates with adverse risk stratification, decreased treatment response and unfavorable survival profiles in elderly acute myeloid leukemia patients Cancer Biomark. 2018 23 3 455 463 10.3233/CBM-181602 30347598
Guo, L., Chen, L. & Wang, H. CD45 correlates with adverse risk stratification, decreased treatment response and unfavorable survival profiles in elderly acute myeloid leukemia patients. Cancer Biomark. 23(3), 455–463 (2018).30347598 10.3233/CBM-181602
47. Guo G Li B Li Q PTPRC overexpression predicts poor prognosis and correlates with immune cell infiltration in pediatric acute myeloid leukemia Clin. Lab. 2022 68 7 210940
Guo, G. et al. PTPRC overexpression predicts poor prognosis and correlates with immune cell infiltration in pediatric acute myeloid leukemia. Clin. Lab. 68(7), 210940 (2022).
48. Staerk J Constantinescu SN The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective JAKSTAT 2012 1 3 184 190 24058768
Staerk, J. & Constantinescu, S. N. The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective. JAKSTAT 1(3), 184–190 (2012).24058768
49. Bader MS Meyer SC JAK2 in myeloproliferative neoplasms: Still a protagonist Pharmaceuticals (Basel) 2022 15 2 160 10.3390/ph15020160 35215273
Bader, M. S. & Meyer, S. C. JAK2 in myeloproliferative neoplasms: Still a protagonist. Pharmaceuticals (Basel) 15(2), 160 (2022).35215273 10.3390/ph15020160
50. Akhtar M Cheng Y Magno RM Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells Cancer Res. 2001 61 6 2399 2403 11289104
Akhtar, M. et al. Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res. 61(6), 2399–2403 (2001).11289104
51. Chien MH Ku CC Johansson G Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway Carcinogenesis 2009 30 12 2005 2013 10.1093/carcin/bgp244 19825968
Chien, M. H. et al. Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis 30(12), 2005–2013 (2009).19825968 10.1093/carcin/bgp244
52. Kiani-Zadeh M Rezvany MR Namjoo S Studying the potential of upregulated PTGS2 and VEGF-C besides hyper-methylation of PTGS2 promoter as biomarkers of acute myeloid leukemia Mol. Biol. Rep. 2022 49 8 7849 7862 10.1007/s11033-022-07615-7 35733068
Kiani-Zadeh, M. et al. Studying the potential of upregulated PTGS2 and VEGF-C besides hyper-methylation of PTGS2 promoter as biomarkers of acute myeloid leukemia. Mol. Biol. Rep. 49(8), 7849–7862 (2022).35733068 10.1007/s11033-022-07615-7
53. Szatkowski D Hellmann A The overexpression of KIT proto-oncogene in acute leukemic cells is not necessarily caused by the gene mutation Acta Haematol. 2015 133 1 116 123 10.1159/000360214 25247397
Szatkowski, D. & Hellmann, A. The overexpression of KIT proto-oncogene in acute leukemic cells is not necessarily caused by the gene mutation. Acta Haematol. 133(1), 116–123 (2015).25247397 10.1159/000360214
54. Valverde LR Matutes E Farahat N C-kit receptor (CD117) expression in acute leukemia Ann. Hematol. 1996 72 1 11 15 10.1007/BF00663010 8605274
Valverde, L. R. et al. C-kit receptor (CD117) expression in acute leukemia. Ann. Hematol. 72(1), 11–15 (1996).8605274 10.1007/BF00663010
55. Cannarile MA Weisser M Jacob W Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy J. Immunother. Cancer 2017 5 1 53 10.1186/s40425-017-0257-y 28716061
Cannarile, M. A. et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J. Immunother. Cancer 5(1), 53 (2017).28716061 10.1186/s40425-017-0257-y
56. Edwards DK V Watanabe-Smith K Rofelty A CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells Blood 2019 133 6 588 599 10.1182/blood-2018-03-838946 30425048
Edwards, D. K. V. et al. CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. Blood 133(6), 588–599 (2019).30425048 10.1182/blood-2018-03-838946
